Marshall Wace
OBIO icon

Marshall Wace’s Orchestra BioMed OBIO Stock Holding History

Marshall Wace’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-188,484
Closed -$801K – 3570
2026
Q1 		$801K Buy
188,484
+16,803
+10% +$71.5K ﹤0.01% 2231
2025
Q4 		$712K Buy
+171,681
New +$693K ﹤0.01% 2093
2025
Q3 		– Sell
-49,465
Closed -$133K – 3255
2025
Q2 		$133K Buy
+49,465
New +$144K ﹤0.01% 2509
2022
Q3 		– Sell
-80,467
Closed -$801K – 3666
2022
Q2 		$801K Hold
80,467
– – ﹤0.01% 2564
2022
Q1 		$798K Hold
80,467
– – ﹤0.01% 2546
2021
Q4 		$803K Buy
80,467
+400
+0.5% +$3.94K ﹤0.01% 2580
2021
Q3 		$792K Buy
+80,067
New +$790K ﹤0.01% 2155
2020
Q4 		– Sell
-20,355
Closed -$224K – 2091
2020
Q3 		$224K Buy
+20,355
New +$229K ﹤0.01% 1436

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Marshall Wace's OBIO Position: Q2 2026 in Review

Marshall Wace sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 188,484 shares — an estimated $801K sold.

Marshall Wace first reported a position in OBIO in Q3 2020 and held it in 8 quarters. The position peaked at $803K in Q4 2021. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Marshall Wace reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 188,484 Orchestra BioMed shares in Q2 2026, an estimated $801K.
  • Marshall Wace first reported a position in Orchestra BioMed in Q3 2020 and held it in 8 quarters.
  • Marshall Wace's Orchestra BioMed position peaked at $803K in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.